Skip to content

Efficacy and safety of esketamine hydrochloride injection at different dosages for patients undergoing radical thyroidectomy for thyroid cancer: a randomized trial.

Yihuan Luo, Hua Fang

BMC Anesthesiology July 1, 2025 DOI: 10.1186/s12871-025-03174-z (opens in new tab)

Read Full Text
Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Sample size 120
Population Patients undergoing radical thyroidectomy
Interventions remimazolam toluene sulfonate esketamine hydrochloride
Dose 0.15, 0.25, and 0.35 mg/kg of esketamine via slow intravenous injection
Topics Esketamine
Keywords Emotion Recovery quality Esketamine dosing Postoperative pain management Surgical recovery Patient comfort
Citations 1
Key findings Esketamine at 0.25 mg/kg and 0.35 mg/kg improves recovery quality, reduces pain and coughing, and maintains hemodynamic stability, with 0.25 mg/kg offering optimal clinical benefits and faster recovery.

Abstract

This study aims to the combination of remimazolam toluene sulfonate and esketamine hydrochloride in reducing postoperative complications and improving recovery outcomes in thyroid surgery patients. One hundred twenty patients undergoing radical thyroidectomy were randomly assigned to four groups: control group (Group C) and three esketamine groups (Groups S1, S2, S3). Before peeling, groups S1, S2, and S3 were administered with 0.15, 0.25, and 0.35 mg/kg of esketamine via slow intravenous injection, respectively. The primary outcomes was recovery quality (QoR-15). Secondary outcomes included postoperative pain (NRS scores), incidence of coughing (Minogue score), hemodynamic stability, emotional recovery (HADS scores), extubation time, adverse reactions, and sufentanil consumption. Baseline data showed no significant differences (p > 0.05). Pain and HADS scores were significantly lower in Groups S2 and S3 (p 0.05). Esketamine at doses of 0.25 mg/kg/h and 0.35 mg/kg/h improves recovery, reduces pain and coughing, and maintains hemodynamic stability. A dose of 0.25 mg/kg/h offers optimal clinical benefits with faster recovery.

Comparable studies

Other randomized controlled trials on esketamine, most cited first.

Study Year Design Participants
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study Adults with moderate to severe nonpsychotic depression and a history of nonresponse to... 2019 Phase 3, double-blind, active-controlled, multicenter randomized controlled trial n = 227
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression Adults with treatment-resistant depression who achieved stable remission or stable... 2019 Phase 3, multicenter, double-blind, randomized withdrawal study n = 297
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression Adults with DSM-IV-TR diagnosis of major depressive disorder and history of inadequate... 2017 Phase 2, double-blind, doubly randomized, delayed-start, placebo-controlled study n = 67
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study Depressed patients at imminent risk for suicide 2018 Randomized controlled trial n = 68
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) Adults with moderate-to-severe depression and nonresponse to at least two... 2019 Randomized controlled trial n = 346

Citations in the library

Cites 2

Related reading

Explore topics

Esketamine Anxiety Depression